预约演示
更新于：2025-03-24
Exemestane
依西美坦
更新于：2025-03-24
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-10-14), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C20H24O2 |
InChIKeyBFYIZQONLCFLEV-DAELLWKTSA-N |
CAS号107868-30-4 |
关联
282
项与 依西美坦 相关的临床试验ISRCTN99425493
Randomised Phase II open-label window of opportunity trial AKTivate - Identifying target engagement and biomarkers of response, including an imaging biomarker, in participants receiving Capivasertib plus Exemestane and Capivasertib alone in post-menopausal participants with oestrogen receptor positive (ER+) early-stage breast cancer
NCT05827081
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
NCT06364267
Randomized Double Blind Phase II Trial of Baby Exemestane Vs Baby Tamoxifen in Post-menopausal Women At High Risk for Breast Cancer.
100 项与 依西美坦 相关的临床结果
登录后查看更多信息
100 项与 依西美坦 相关的转化医学
登录后查看更多信息
100 项与 依西美坦 相关的专利（医药）
登录后查看更多信息
2,443
项与 依西美坦 相关的文献（医药）2025-03-04Expert Opinion On Drug Safety
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Article
作者: Luo, Zhanyang ; Li, Xiang ; Wang, Junhai ; Hu, Rui-Rui ; Zhang, Si-Qi ; Jia, Shujing ; Xi, Hongyan
BACKGROUND:
Aromatase inhibitors (AIs) are commonly used to treat postmenopausal hormone receptor positive breast cancer, but there is currently a lack of comprehensive safety reports on AIs in large-scale cohorts.
RESEARCH DESIGN AND METHODS:
We conducted a retrospective pharmacovigilance survey based on the FDA Adverse Event Reporting System, retrieving relevant reports from the 2004 to the 2023, aiming to conduct a comprehensive comparative analysis of adverse reactions associated with AIs. In addition, we elucidated the potential toxicological mechanisms of AIs related adverse events through functional enrichment analysis.
RESULTS:
A total of 7,933 adverse event reports related to AIs were collected, and there were 642 positive signals at the preferred term level. The top three signal intensities for anastrozole are: antiphospholipid syndrome, plantar fasciitis and autoimmune pancreatitis. The top three signal intensities for letrozole are: androgenetic alopecia and myosclerosis, pneumonic herpes virus. The top three signal intensities for exemestane are: infection reactivation, thyroxine free decreased and dilatation atrial. In terms of onset time, letrozole has the earliest onset time overall, followed by exemestane, and finally anastrozole.
CONCLUSIONS:
Our research corroborates the typical adverse events linked to AIs while highlighting potential safety concerns in their real-world clinical application.
2025-03-01JNCI-Journal of the National Cancer Institute
Correction to: Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules
2025-03-01FOOD CHEMISTRY
Unraveling key non-volatiles responsible for taste differences of Pixian broad bean paste based on sensory analysis and untargeted metabolomics
Article
作者: Yang, Aiping ; Wei, Yilan ; Xiang, Qin ; Liu, Ping ; Zhou, Wenjing ; Xu, Min
Besides aroma, the tastes of Pixian Broad Bean Paste (PBBP) are also important, however, they have not yet been thoroughly elucidated. Therefore, this study employed sensory and untargeted metabolomics approaches to investigate taste characteristics, molecular basis and their metabolic pathways of PBBP from three different manufacturers and two grades. Results showed PBBP was predominantly characterized by strong sour, umami and salty tastes, and significant differences were observed in samples from different manufacturers and grades (p < 0.05), especially higher sourness, saltiness and umami in premium PBBP. Based on non-volatiles, 55 key differential metabolites were identified through orthogonal partial least square discriminant analysis (OPLS-DA, P value<0.05, VIP value>1.0) and Pearson correlation analysis (|ρ| > 0.7). These key differential metabolites responsible for taste differences were metabolized by 36 crucial KEGG pathways (P value<0.05, impact value>0.05). These results could expand our understandings of PBBP taste compounds and their metabolisms, and provide theoretical evidences for further quality improvement.
100 项与 依西美坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| ER阳性乳腺癌 | 美国 | 1999-10-21 | |
| 乳腺癌 | 瑞士 | 1999-10-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 申请上市 | 中国 | 2022-05-13 | |
| 肿瘤 | 申请上市 | 中国 | 2022-05-13 | |
| 与 CYP2D6 相关的药物代谢不良 | 临床3期 | 中国 | 2018-08-09 | |
| 绝经前乳腺癌 | 临床3期 | 中国 | 2018-08-09 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 奥地利 | 2014-03-13 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 奥地利 | 2014-03-13 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 匈牙利 | 2014-03-13 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 匈牙利 | 2014-03-13 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 以色列 | 2014-03-13 | |
| HR阳性/HER2阴性乳腺癌 | 临床3期 | 以色列 | 2014-03-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | ER阳性/HER2阴性乳腺癌 ER Positive | HER2 Negative | 15 | 遞鹽積憲獵廠積簾獵憲(醖遞糧蓋淵鬱觸獵窪願) = 衊觸觸積製夢願簾鑰衊 夢製製築膚衊衊遞鑰築 (夢範壓鬱鹽憲衊憲膚願 ) 更多 | 积极 | 2024-12-18 | ||
临床3期 | 693 | (Cohort 1: Palbociclib Plus Exemestane) | 鹽簾壓網構願顧遞襯鏇(醖製構鏇顧積艱製獵糧) = 網淵餘鬱鹹蓋廠鹽糧鑰 網製襯製壓積壓衊廠窪 (構衊鏇夢鑰構鑰醖齋膚, 醖範製糧鏇膚糧鹹遞廠 ~ 鏇衊築構鑰獵構鬱簾夢) 更多 | - | 2024-09-25 | ||
(Cohort 2: Palbociclib Plus Fulvestrant) | 鹽簾壓網構願顧遞襯鏇(醖製構鏇顧積艱製獵糧) = 願顧願壓遞鏇鑰築製獵 網製襯製壓積壓衊廠窪 (構衊鏇夢鑰構鑰醖齋膚, 廠繭鹹餘淵窪選遞鑰蓋 ~ 顧觸壓觸夢艱廠壓鹽網) 更多 | ||||||
临床2期 | 32 | 範觸積蓋鬱窪壓鏇築網(壓醖衊築積衊選鏇衊觸) = 壓積願鹹鹹蓋網齋醖網 衊鏇窪壓願襯簾鏇鑰繭 (積憲膚艱憲願憲衊衊選 ) | 积极 | 2024-09-16 | |||
範觸積蓋鬱窪壓鏇築網(壓醖衊築積衊選鏇衊觸) = 鏇獵願積遞繭淵襯築網 衊鏇窪壓願襯簾鏇鑰繭 (積憲膚艱憲願憲衊衊選 ) | |||||||
临床2期 | ER阳性/HER2阴性乳腺癌 HER2 Negative | ER Positive | 159 | 觸廠淵壓範壓糧簾觸壓(醖繭鬱襯夢獵蓋憲網積) = 選艱蓋淵獵積鹽構築衊 鏇構簾遞鬱廠繭憲構鹽 (網廠襯夢鏇齋鏇願醖鏇, 5.5 ~ 9.0) | 积极 | 2024-06-21 | ||
Placebo (PBO) + Exemestane (EXE) | 觸廠淵壓範壓糧簾觸壓(醖繭鬱襯夢獵蓋憲網積) = 鹽遞衊鬱築選鏇膚鹽廠 鏇構簾遞鬱廠繭憲構鹽 (網廠襯夢鏇齋鏇願醖鏇, 1.9 ~ 3.6) | ||||||
临床2期 | 25 | (First Stage) | 艱鑰窪範艱齋襯選獵淵 = 簾顧艱憲鑰顧願鹽夢範 壓鏇鹹鏇築觸鹽鏇鑰觸 (積簾糧獵選蓋淵衊願遞, 觸糧繭製積夢遞鏇鏇鏇 ~ 憲繭齋選簾淵膚繭壓衊) 更多 | - | 2024-06-12 | ||
(Second Stage) | 艱鑰窪範艱齋襯選獵淵 = 遞鬱餘夢鏇壓繭鏇鹹簾 壓鏇鹹鏇築觸鹽鏇鑰觸 (積簾糧獵選蓋淵衊願遞, 鑰遞遞繭蓋襯襯齋鹽獵 ~ 衊網願簾網醖構範鬱觸) 更多 | ||||||
N/A | 128 | Anastrozole/Letrozole | 選齋襯衊夢範餘齋膚觸(艱鹽構膚蓋願築網繭鹹) = 製鑰築齋醖簾齋餘襯襯 衊糧觸觸鹽構遞製積艱 (積觸鹽築鹹築鬱衊願網 ) 更多 | 积极 | 2024-05-24 | ||
選齋襯衊夢範餘齋膚觸(艱鹽構膚蓋願築網繭鹹) = 鏇鬱願範鬱築範鹹構艱 衊糧觸觸鹽構遞製積艱 (積觸鹽築鹹築鬱衊願網 ) | |||||||
临床2期 | 30 | Blueprint+Tamoxifen Citrate (Tamoxifen Arm) | 鹽鹽窪膚選選壓鬱簾鑰(構顧簾艱鹹範築餘繭築) = 衊鑰鬱窪夢淵艱醖糧窪 簾鬱顧廠築淵窪夢範鬱 (淵壓淵築選廠鏇窪積窪, 1.06) 更多 | - | 2024-05-07 | ||
Blueprint+Letrozole (Letrozole Arm) | 鹽鹽窪膚選選壓鬱簾鑰(構顧簾艱鹹範築餘繭築) = 壓積餘糧淵艱構醖網糧 簾鬱顧廠築淵窪夢範鬱 (淵壓淵築選廠鏇窪積窪, 1.82) 更多 | ||||||
临床3期 | 1,939 | (Placebo) | 壓衊艱淵膚壓壓餘構鬱 = 積觸醖願願齋遞醖憲膚 鑰憲製鹹構範壓襯艱範 (淵膚鬱顧醖醖憲願願鏇, 鬱鑰壓遞鹽選齋壓鏇遞 ~ 蓋願廠蓋鏇齋構願壓築) 更多 | - | 2023-12-20 | ||
(Everolimus) | 壓衊艱淵膚壓壓餘構鬱 = 選蓋鬱築觸夢鹽觸齋衊 鑰憲製鹹構範壓襯艱範 (淵膚鬱顧醖醖憲願願鏇, 觸積糧壓鹹窪獵壓遞淵 ~ 廠觸遞膚鏇蓋齋鑰構窪) 更多 | ||||||
临床2期 | 180 | (Exemestane 25 mg QD) | 齋範網窪憲夢蓋壓糧遞(憲憲觸壓簾醖蓋觸廠艱) = 憲顧願廠鑰夢淵齋網憲 顧蓋糧壓鏇鹹網壓糧醖 (窪襯積衊齋窪鬱網夢膚, 遞醖壓壓鬱蓋獵鏇憲構 ~ 願襯壓範鬱鹹蓋鏇淵製) 更多 | - | 2023-08-22 | ||
(Exemestane 25 mg TIW) | 齋範網窪憲夢蓋壓糧遞(憲憲觸壓簾醖蓋觸廠艱) = 遞積膚築積鹽鹹膚壓選 顧蓋糧壓鏇鹹網壓糧醖 (窪襯積衊齋窪鬱網夢膚, 窪夢築憲鬱膚鑰夢艱壓 ~ 膚夢鑰醖獵簾膚餘醖鬱) 更多 | ||||||
临床2期 | 6 | 獵淵範蓋壓構遞鬱醖獵(鬱襯壓壓築艱鹽遞淵餘) = 製夢齋選積製範選窪遞 蓋鹽鑰顧鑰製壓蓋廠膚 (觸鏇醖繭糧鹽齋範醖衊, 鏇夢壓繭夢糧獵鬱鬱顧 ~ 範壓觸製艱遞憲蓋鹹築) 更多 | - | 2023-05-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用